Knight Therapeutics (TSE:GUD) Price Target Cut to C$7.50 by Analysts at Raymond James

Knight Therapeutics (TSE:GUD) had its target price lowered by Raymond James from C$8.00 to C$7.50 in a research note published on Thursday morning,BayStreet.CA reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

Several other research firms have also recently issued reports on GUD. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from C$5.75 to C$6.75 in a report on Tuesday, August 13th. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Knight Therapeutics Price Performance

Shares of GUD stock opened at C$5.19 on Thursday. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. The firm has a market capitalization of C$525.28 million, a price-to-earnings ratio of -25.95, a PEG ratio of -1,013.50 and a beta of 0.50. The firm’s 50 day moving average is C$5.71 and its 200-day moving average is C$5.73. Knight Therapeutics has a 1 year low of C$5.07 and a 1 year high of C$6.23.

Insider Buying and Selling

In other Knight Therapeutics news, insider Sime Armoyan sold 300,000 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00. Also, Director Samira Sakhia acquired 20,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of C$5.15 per share, for a total transaction of C$103,000.00. 45.62% of the stock is owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.